Expression of Vascular Endothelial Growth Factor Correlates with the Advance of Clinical Osteosarcoma

Overview

Journal Int Orthop

Specialty Orthopedics

Date 2012 Aug 3

PMID 22855059

Citations 25

Authors

John Lammli

Minyan Fan

Howard G Rosenthal

Meghan Patni

Elizabeth Rinehart

Gerardo Vergara

Elizabeth Ablah

Paul H Wooley

George Lucas

Shang-You Yang

Affiliations

Soon will be listed here.

Abstract

Purpose: Osteosarcoma is the most common primary malignancy in orthopaedic surgery. Studies suggest that expression of VEGF and high vascularity within osteosarcoma may correlate with poor prognosis. The purpose of this study was to determine whether there was a correlation of VEGF expression with clinical tumour stage and metastasis.

Methods: This retrospective case series examined 54 cases of osteosarcoma patients who were treated during a ten-year period. Relevant clinical information included age, gender, tumour location, stage, adjuvant therapy, morbidity, mortality, and tumour subtypes. The clinical information was analysed for correlation of VEGF expression and tumour prognosis. Tumour sections were examined by routine H&E and by immunohistochemistry for VEGF, CD31, and the oncogenes c-myc and c-fos.

Results: There was a significantly positive correlation between VEGF expression and tumour stages among these cases (p < 0.01). The data also suggested a higher cancer recurrence and more frequent cases of remote metastasis in the high-VEGF group compared to the low-VEGF group. VEGF expression also positively associated with c-fos and c-myc expressions in the primary tumour sections.

Conclusion: The results of this study highlight the role of VEGF in angiogenesis and tumour burden. Data also suggest the influence of VEGF may associate with the elevations of c-fos and c-myc expression. The development of novel therapies to target the VEGF pathway in osteosarcoma may lead to improved survival.

Citing Articles

NOTCH Signaling in Osteosarcoma.

Zhang Z, Wu W, Shao Z Curr Issues Mol Biol. 2023; 45(3):2266-2283.

PMID: 36975516 PMC: 10047431. DOI: 10.3390/cimb45030146.

ETC-159, an Upstream Wnt inhibitor, Induces Tumour Necrosis via Modulation of Angiogenesis in Osteosarcoma.

Chua K, Sim A, Yeo E, Bin Masroni M, Naw W, Leong S Int J Mol Sci. 2023; 24(5).

PMID: 36902186 PMC: 10003732. DOI: 10.3390/ijms24054759.

A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody.

Hayashi T, Yamamoto N, Kurosawa G, Tajima K, Kondo M, Hiramatsu N Cancers (Basel). 2022; 14(23).

PMID: 36497311 PMC: 9739802. DOI: 10.3390/cancers14235829.

The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.

Zhang C, Wang L, Xiong C, Zhao R, Liang H, Luo X J Orthop Surg Res. 2021; 16(1):738.

PMID: 34963495 PMC: 8715589. DOI: 10.1186/s13018-021-02888-3.

Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review.

Rijs Z, Jeremiasse B, Shifai N, Gelderblom H, Sier C, Vahrmeijer A Biomedicines. 2021; 9(10).

PMID: 34680505 PMC: 8533294. DOI: 10.3390/biomedicines9101388.

References

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

van den Berg S, Rahmsdorf H, Herrlich P, Kaina B . Overexpression of c-fos increases recombination frequency in human osteosarcoma cells. Carcinogenesis. 1993; 14(5):925-8. DOI: 10.1093/carcin/14.5.925. View

Folkman J . Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2003; 29(6 Suppl 16):15-8. DOI: 10.1053/sonc.2002.37263. View

Yang S, Yu H, Krygier J, Wooley P, Mott M . High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. Sarcoma. 2008; 2007:95628. PMC: 2225469. DOI: 10.1155/2007/95628. View

Weidner N, Folkman J . Tumoral vascularity as a prognostic factor in cancer. Important Adv Oncol. 1996; :167-90. View

Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y . Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 1996; 56(13):3004-9. View

Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H . Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer. 1998; 77(6):998-1002. PMC: 2150098. DOI: 10.1038/bjc.1998.164. View

Rosen G, Suwansirikul S, Kwon C, Tan C, Wu S, Beattie Jr E . High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. Cancer. 1974; 33(4):1151-63. DOI: 10.1002/1097-0142(197404)33:4<1151::aid-cncr2820330439>3.0.co;2-8. View

Coomber B, Denton J, Sylvestre A, Kruth S . Blood vessel density in canine osteosarcoma. Can J Vet Res. 1998; 62(3):199-204. PMC: 1189476. View

10.

McMahon G . VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000; 5 Suppl 1:3-10. DOI: 10.1634/theoncologist.5-suppl_1-3. View

11.

Pompetti F, Rizzo P, Simon R, Freidlin B, Mew D, Pass H . Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem. 1996; 63(1):37-50. DOI: 10.1002/(SICI)1097-4644(199610)63:1%3C37::AID-JCB3%3E3.0.CO;2-0. View

12.

Takayama K, Ueno H, Nakanishi Y, Sakamoto T, Inoue K, Shimizu K . Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000; 60(8):2169-77. View

13.

Lee Y, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, TOMISAWA M . Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999; 35(7):1089-93. DOI: 10.1016/s0959-8049(99)00073-8. View

14.

Roland C, Dineen S, Lynn K, Sullivan L, Dellinger M, Sadegh L . Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009; 8(7):1761-71. DOI: 10.1158/1535-7163.MCT-09-0280. View

15.

Yin D, Jia T, Gong W, Yu H, Wooley P, Mott M . VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int J Oncol. 2008; 33(2):253-9. View

16.

Ben-Josef E, Yang S, Ji T, Bidart J, Garde S, Chopra D . Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol. 1999; 161(3):970-6. View

17.

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I . Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2008; 17(2):278-84. PMC: 2835051. DOI: 10.1038/mt.2008.258. View

18.

Jia Z, Jiang G, Feng Y . Serum HIF-1alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2012; 26(3):158-62. DOI: 10.1016/s1001-9294(11)60041-2. View

19.

Yuan A, Yu C, Kuo S, Chen W, Lin F, Luh K . Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001; 19(2):432-41. DOI: 10.1200/JCO.2001.19.2.432. View

20.

Cole M, McMahon S . The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 1999; 18(19):2916-24. DOI: 10.1038/sj.onc.1202748. View